NanoKnife (Prostate Tissue Ablation System)

History

2024: Product Announcement

In mid-December 2024, AngioDynamics introduced the NanoKnife system for ablation of prostate tissue in patients with prostate cancer. This machine removes tumor tissue using microneedles without affecting urine excretion and sexual function.

Prostate cancer is the second most common cancer in men worldwide. 1.5 million cases are diagnosed annually, and many patients are looking for alternatives to radical treatment, which can lead to serious long-term side effects. The NanoKnife system uses non-thermal, non-radiation irreversible electroporation (IRE) technology to accurately ablate prostate tissue using microneedles. It is a minimally invasive alternative to traditional surgery and radiotherapy that reduces recovery time and preserves urinary and sexual functions.

𝓲

angiodynamics.com

The 121-patient PRESERVE pivotal clinical trial demonstrated the safety and efficacy of the new system. One year after surgery, 84% of patients did not report any clinically relevant symptoms. In addition, the study produced favorable quality of life scores, including for urinary retention and minimal reduction in erectile function. According to the developers, the NanoKnife system minimizes complications that often occur with traditional treatments by selectively affecting prostate tissue, which significantly increases patient satisfaction with treatment.

AngioDynamics plans to support the implementation of the NanoKnife system among physicians and patients through comprehensive training as well as other outreach initiatives so that patients can evaluate all available treatment options.^[1]

Notes